Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ETP-46321

 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

ImidazolesPyrazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Identification of novel PI3K inhibitors through a scaffold hopping strategy.
A scaffold hopping strategy, including intellectual property availability assessment, was successfully applied for the discovery… Expand
2017
2017
Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy.
The involvement of the phosphoinositide 3-kinases (PI3Ks) in several diseases, especially in the oncology area, has singled it as… Expand
2016
2016
ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
Class IA phosphoinositide 3-kinases (PI3Ks) are essential to function of normal and tumor cells, and to modulate immune responses… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2012
2012
Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.
Phosphoinositide-3-kinase (PI3K) is an important target for cancer therapeutics due to the deregulation of this signaling pathway… Expand
2012
2012
Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases
SummaryInhibitors of PI3K signaling are of great therapeutic interest in oncology. The phosphoinositide-3-kinase signaling… Expand
  • figure 1
  • table 1
  • figure 3
  • figure 4
  • figure 5
2010
2010
134 Biological characterization of ETP-46321 a potent and selective phosphoinositide-3-kinase inhibitor with antitumor activity
 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE